Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CHIR-124 + Gemcitabine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CHIR-124||CHK1 Inhibitor 14||CHIR-124 is a selective inhibitor of CHK1, which may enhance sensitivity of tumor cells to chemotherapeutic agents (PMID: 17255282, PMID: 22244109).|
|Gemcitabine||Gemzar||Difluorodeoxycytidine Hydrochlorothiazide|LY-188011||Chemotherapy - Antimetabolite 11||Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||pancreatic cancer||not applicable||CHIR-124 + Gemcitabine||Preclinical - Cell culture||Actionable||In a preclinical study, CHIR-124 and Gemzar (gemcitabine) demonstrated synergistic cytoxicity in pancreatic cancer cells in spheroid culture, resulting in increased DNA damage and apoptosis and decreased viability (PMID: 22244109).||22244109|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|